Commenting on the results of the human lung tissue study, RS BioTherapeutics’ Chief Executive Officer, Dean Hart said, “These results of the impact of RSBT-001 on key inflammatory biomarkers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback